FENC Relative Valuation
FENC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FENC is overvalued; if below, it's undervalued.
Historical Valuation
Fennec Pharmaceuticals Inc (FENC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 4.66. The fair price of Fennec Pharmaceuticals Inc (FENC) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：7.51
Fair
16.10
PE
1Y
3Y
5Y
Trailing
Forward
8.23
EV/EBITDA
Fennec Pharmaceuticals Inc. (FENC) has a current EV/EBITDA of 8.23. The 5-year average EV/EBITDA is 3.92. The thresholds are as follows: Strongly Undervalued below -21.42, Undervalued between -21.42 and -8.75, Fairly Valued between 16.58 and -8.75, Overvalued between 16.58 and 29.25, and Strongly Overvalued above 29.25. The current Forward EV/EBITDA of 8.23 falls within the Historic Trend Line -Fairly Valued range.
15.34
EV/EBIT
Fennec Pharmaceuticals Inc. (FENC) has a current EV/EBIT of 15.34. The 5-year average EV/EBIT is 17.20. The thresholds are as follows: Strongly Undervalued below -141.47, Undervalued between -141.47 and -62.14, Fairly Valued between 96.54 and -62.14, Overvalued between 96.54 and 175.88, and Strongly Overvalued above 175.88. The current Forward EV/EBIT of 15.34 falls within the Historic Trend Line -Fairly Valued range.
3.72
PS
Fennec Pharmaceuticals Inc. (FENC) has a current PS of 3.72. The 5-year average PS is 17.14. The thresholds are as follows: Strongly Undervalued below -58.41, Undervalued between -58.41 and -20.63, Fairly Valued between 54.91 and -20.63, Overvalued between 54.91 and 92.69, and Strongly Overvalued above 92.69. The current Forward PS of 3.72 falls within the Historic Trend Line -Fairly Valued range.
7.03
P/OCF
Fennec Pharmaceuticals Inc. (FENC) has a current P/OCF of 7.03. The 5-year average P/OCF is -35.52. The thresholds are as follows: Strongly Undervalued below -374.08, Undervalued between -374.08 and -204.80, Fairly Valued between 133.77 and -204.80, Overvalued between 133.77 and 303.05, and Strongly Overvalued above 303.05. The current Forward P/OCF of 7.03 falls within the Historic Trend Line -Fairly Valued range.
7.03
P/FCF
Fennec Pharmaceuticals Inc. (FENC) has a current P/FCF of 7.03. The 5-year average P/FCF is -29.43. The thresholds are as follows: Strongly Undervalued below -365.55, Undervalued between -365.55 and -197.49, Fairly Valued between 138.62 and -197.49, Overvalued between 138.62 and 306.68, and Strongly Overvalued above 306.68. The current Forward P/FCF of 7.03 falls within the Historic Trend Line -Fairly Valued range.
Fennec Pharmaceuticals Inc (FENC) has a current Price-to-Book (P/B) ratio of -47.29. Compared to its 3-year average P/B ratio of -32.95 , the current P/B ratio is approximately 43.54% higher. Relative to its 5-year average P/B ratio of -13.04, the current P/B ratio is about 262.69% higher. Fennec Pharmaceuticals Inc (FENC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 0.32%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -3.21% , the current FCF yield is about -100.00% lower.
-48.60
P/B
Median3y
-32.95
Median5y
-13.04
-3.09
FCF Yield
Median3y
0.32
Median5y
-3.21
Competitors Valuation Multiple
The average P/S ratio for FENC's competitors is 0.00, providing a benchmark for relative valuation. Fennec Pharmaceuticals Inc Corp (FENC) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 78.69%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of FENC increased by 23.10% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 6.97M to 12.46M.
The secondary factor is the P/E Change, contributed 38.18%to the performance.
Overall, the performance of FENC in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Fennec Pharmaceuticals Inc (FENC) currently overvalued or undervalued?
What is Fennec Pharmaceuticals Inc (FENC) fair value?
How does FENC's valuation metrics compare to the industry average?
What is the current P/B ratio for Fennec Pharmaceuticals Inc (FENC) as of Dec 05 2025?
What is the current FCF Yield for Fennec Pharmaceuticals Inc (FENC) as of Dec 05 2025?
What is the current Forward P/E ratio for Fennec Pharmaceuticals Inc (FENC) as of Dec 05 2025?